LC
AVXL icon

Lindbrook Capital’s Anavex Life Sciences AVXL Stock Holding History

Lindbrook Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$16.4K Hold
1,914
– – ﹤0.01% 1440
2024
Q4 		$20.6K Hold
1,914
– – ﹤0.01% 1276
2024
Q3 		$10.9K Buy
1,914
+109
+6% +$629 ﹤0.01% 1633
2024
Q2 		$7.62K Buy
1,805
+1,617
+860% +$6.54K ﹤0.01% 1783
2024
Q1 		$957 Sell
188
-421
-69% -$2.37K ﹤0.01% 2430
2023
Q4 		$5.67K Buy
+609
New +$4.19K ﹤0.01% 1821
2022
Q4 		– Sell
-39
Closed – – 2838
2022
Q3 		$0 Buy
+39
New +$412 ﹤0.01% 2619

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Lindbrook Capital's AVXL Position: Q1 2025 in Review

Lindbrook Capital held its Anavex Life Sciences (AVXL) position steady in Q1 2025 at 1,914 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Lindbrook Capital first reported a position in AVXL in Q3 2022 and has held it in 7 quarters since. The position peaked at $20.6K in Q4 2024. 181 funds tracked by Wall St. Rank hold AVXL as of Q1 2025.

  • Lindbrook Capital held 1,914 shares of Anavex Life Sciences worth $16.4K as of Q1 2025.
  • Lindbrook Capital left its Anavex Life Sciences share count unchanged in Q1 2025.
  • Anavex Life Sciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1440 holding.
  • Lindbrook Capital first reported a position in Anavex Life Sciences in Q3 2022 and has held it in 7 quarters since.
  • Lindbrook Capital's Anavex Life Sciences position peaked at $20.6K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.